<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320496">
  <stage>Registered</stage>
  <submitdate>12/09/2010</submitdate>
  <approvaldate>20/09/2010</approvaldate>
  <actrnumber>ACTRN12610000779077</actrnumber>
  <trial_identification>
    <studytitle>Bromocriptine effect on left ventricular hypertrophy in patients with diabetic nephropathy</studytitle>
    <scientifictitle>Bromocriptine effect on left ventricular hypertrophy in patients with diabetic nephropathy</scientifictitle>
    <utrn />
    <trialacronym>BELVHD</trialacronym>
    <secondaryid>Cochrane Renal Group: CRG020600041</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Left  ventricular hypertrophy</healthcondition>
    <healthcondition>Type 2 diabetes mellitus  (DM2)</healthcondition>
    <healthcondition>Stage IV of chronic kidney disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Bromocriptine  oral tablets 2.5 mg  or bromocriptine placebo oral tablets 2.5 mg .  The  daily doses  administered were as follows:  Week 1: 1x2.5 mg oral tablet  per day, taken after the night meal;Week 2: 2 x 2.5 mg oral tablets per day  (5 mg), taken in the morning meal and after the night meal; Weeks 3 - 24 : 3 x 2.5 mg oral tablets per day (7.5 mg)  taken after meals. The subjects received this medication  in addition to their current treatment.</interventions>
    <comparator>The placebo oral tablets looks like the bromocriptine tablets, same color, size  and appearance, but made of starch.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in left ventricular hypertrophy, assessed by two dimensionally guided M-mode echocardiography). This  study was done by an expert who didn't know the treatment of the patients, and he followed the  recomendations of the American Society of Cardiology. The measures   assesed were: left ventricular mass, left ventricular posterior wall thikness, left ventricular septum thikness, left ventricular diastolic diameter and   left ventricular mass index that was calculated according  with Devereux formula.</outcome>
      <timepoint>Baseline, three and six months following randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Systolic, diastolic and mean blood pressured assesed by 24h ambulatory blood pressure, using  a 24 h ambulatory non invasive device.</outcome>
      <timepoint>Baseline, three and six months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>24h creatinine clearance. assessed in a 24h urine sample and blood sample.</outcome>
      <timepoint>Baseline, three and six months after randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pro brain natriuretic peptide,determined  in blood sample after a fasting period of 10 h. the samples were obtained after  30 minutes resting in bed.</outcome>
      <timepoint>Baseline, three and six months after randomization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prolactin plasma levels determined in blood samples</outcome>
      <timepoint>Baseline and three and six months following randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>type 2 diabetes mellitus
Left ventricular mass &gt; or = 116 g/m2in men and 104 g/m2 in women.
Creatinine clearance &lt; or =30 ml/min.
24h Ambulatory  blood pressure (AMBP) &gt; or = 130/80 mmHg. 
Patients who give written informed consent</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients treated with  dopamine (DA2) receptors antagonists.

Cardiac insuficiency.

Cardiac stroke.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects were randomised through  table of random numbers by  permuted block randomization, that were saved in opaque sealed envelopes.</concealment>
    <sequence>A table of random numbers were used.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>19/11/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Michoacan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Escuela Superior de Medicina del Instituto Politecnico Nacional  (IPN)</primarysponsorname>
    <primarysponsoraddress>Plan de San Luis y Diaz Miron.
Mexico D.F.  C.P.  11340</primarysponsoraddress>
    <primarysponsorcountry>Mexico</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Fondo de Fomento a la Investigacion del Instituto mexicano del Seguro Social</fundingname>
      <fundingaddress>Paseo de la Reforma  No 476. 
Colonia Juarez. Delegacion Cuauhtemoc. 
 CP. 06600 . Mexico DF</fundingaddress>
      <fundingcountry>Mexico</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Unidad de Medicna Familiar No 80 del Instituto Mexicano del Seguro Social (IMSS)</sponsorname>
      <sponsoraddress>Ave Madero poniente 1200. Colonia Centro
Morelia, Michoacan, C.P. 58000</sponsoraddress>
      <sponsorcountry>Mexico</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Hospital General  Regional  No 1/ Unidad de Medicina Familiar No 80 del Instituto Mexicano del Seguro Social</sponsorname>
      <sponsoraddress>Ave Heroes de Nocupetaro S/N 
Morelia, Michoacan . CP. 58010
Mexico</sponsoraddress>
      <sponsorcountry>Mexico</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Left ventricular hypertrophy (LVH) is a major cardiovascular risk factor in patients with diabetic nephropathy and chronic kidney disease (CKD), it predicts myocardial infarction, stroke and cardiovascular death. The prevalence of LVH increases as the renal function declines. High blood pressure, obesity and abnormal lipid profile which often coexist with diabetes have an important role in its development. The mechanism by which LVH develops includes activation of the renin-angiotensin system, aldosterone secretion, and sympathetic over activity. Bromocriptine a DA2 receptor agonist inhibits norepinephrine release and decrease blood pressure acting at the presynaptic receptors. In the kidney it mediates vasodilatation and decreases tubular sodium reabsorption, it also decreases the expression of type-1 angiotensin II receptors in renal proximal tubule and inhibits aldosterone secretion. All of these actions could exert an antiproliferative effect on LVH and modulate kidney function.
The objective of this study was to analyze the effect of bromocriptine on left ventricular hypertrophy and its influence in residual renal function in patients with diabetic nephropathy, LVH and stage IV of CKD.</summary>
    <trialwebsite />
    <publication>5to Congreso Estatal de Ciencia y Tecnologia clebrated in Morelia, Michoacan , Mexico. Date: november 12 and 13 2009.
Poster presentation: "Efecto de bromocriptina en la hipertrofia ventricular izquierda en pacientes  con nefropatia diabetica IV"

XXI Congreso Nacional de Medicina Familiar
Date: 1  to may 3 2008
Guadalajara , Jalisco. Mexico
Poster presentation. "Efecto de bromocriptina en la hipertrofia ventricular izquierda en pacientes  con nefropatia diabetica IV"</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite Local de Investigacion  No 1602</ethicname>
      <ethicaddress>Instituto Mexicano del Seguro Social 
Hospital General Regional No 1
Ave Nocupetaro S/N 
C.P. 58010
Morelia, Michoacan . Mexico</ethicaddress>
      <ethicapprovaldate>23/10/2003</ethicapprovaldate>
      <hrec>2003.296.00016</hrec>
      <ethicsubmitdate>2/09/2003</ethicsubmitdate>
      <ethiccountry>Mexico</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr, Oliva, Mejia-Rodriguez</name>
      <address>Instituto Mexicano del Seguro Social 
Unidad de Medicina Familiar No 80
Avenida Madero poniente No 1200
Morelia, Michoacan
C.P. 58000</address>
      <phone>52 443 3 12 28 80  ext 31407</phone>
      <fax>52 443 3 13 70 26</fax>
      <email>olivamejia@yahoo.com</email>
      <country>Mexico</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Ramon Paniagua-Sierra</name>
      <address>Unidad de Investigacion en Enfermedades Nefrologicas
Centro Medico Nacional Siglo XXI. IMSS
Ave Cuauhtemoc No 330
Col. Doctores 
MÃ©xico DF. C.P. 06725</address>
      <phone>52 55 57 52 59 67 ext 21371</phone>
      <fax />
      <email>ramon.paniagua@imss.gob.mx</email>
      <country>Mexico</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Oliva Mejia-Rodriguez</name>
      <address>Instituto Mexicano del Seguro Social 
Unidad de Medicina Familiar No 80
Avenida Madero poniente No 1200
Morelia, Michoacan
C.P. 58000</address>
      <phone>52 443 3 12 28 80 ext 31407</phone>
      <fax />
      <email>olivamejia@yahoo.com</email>
      <country>Mexico</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>